BOX S–1
Committee on Identifying and Prioritizing New Preventive
Vaccines for Development

Institute of Medicine
Phase I
Statement of Task

Task 1: Review domestic and global research and development prioritization activities relevant to identifying new preventive vaccine targets.

Task 2: Develop an analytical framework and model for prioritizing vaccines of domestic and global importance. Engage stakeholders to inform the process of the model development and implementation.

Task 3: Test and validate the model using two to three predetermined vaccines, including at least one vaccine candidate of domestic importance and one of global importance.

Task 4: Prepare a report containing the analytical framework and model for evaluating and prioritizing vaccine targets along with recommendations as to how to use the model for reviewing the catalog of preventive vaccines every 2 to 3 years.

international perspective, based on infant mortality equivalents—a proxy measure of health burden.

The 2000 report Vaccines for the 21st Century focused entirely on the U.S. population and, unlike the 1985–1986 report, used an efficiency measure for ranking vaccines: incremental cost per incremental quality-adjusted life years saved ($/QALY), a measure derived from a classic welfare economics model. The cost-effectiveness model of the 2000 report represented important progress toward vaccine prioritization, but it did not provide guidance for answering some challenging questions often encountered in decision making. For instance, the model provided no guidance on how to choose between two diseases with equal QALYs when one was a low-impact disease affecting the majority of the population and the other a disease with few cases but with very high mortality and potential large-scale social disruption.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement